近日， 国科离子医疗科技有限公司 宣布完成 首轮股权融资，募集资金约 8 亿元人民币 。 本轮融资由 社保 基金中关村自主创新专项基金（君联资本担任管理人） 与 君联资本 联合领投，资金将主要用于重离子及轻离 子治疗装备的持续研发、产业化推进及治疗中心布局。 这是近年来 国内粒子治疗装备领域金额较大的一笔市场化融资 ，也标志着国产重离子治疗系统正从技术验证 阶段，进一步走向规模化落地。 # 从科研装 置到临 床系统，重离子治疗实现国产突破 国科离子及其全资控股公司 兰州泰基离子技术有限公司 ，依托中国科学院近代物理研究所 三代人、50 余年 的重离子物理与医用加速器研究积累 ，已在肿瘤治疗装备产业化领域深耕 20 余年。 据公司公开信息，2019 年，公司成功研制出 我国首台拥有完全自主知识产权的碳离子治疗系统 ，并于 2020 年投入临床应用，打破了重离子放疗长期依赖进口的技术格局，使中国成为 全球第 4 个掌握重离子治 癌核心技术的国家 。 目前，该系统已在 甘肃武威等地实现稳定临床运行 ，并完成从科研装置向医疗器械体系的转化。 # 轻离子联合治疗装置落地，指向"降成本、提可及性" 据公开信息，重离子系统 ...

Core Insights - Guoke Ion Medical Technology Co., Ltd. has successfully raised 800 million yuan in its first round of equity financing, led by the Social Security Fund's Zhongguancun Independent Innovation Special Fund and Junlian Capital, with additional investment from existing shareholder Xiamen Guomao [1][2] Group 1: Company Overview - Guoke Ion aims to create a comprehensive heavy ion therapy industry that integrates high-end equipment manufacturing, precision digital healthcare, and operational maintenance services [1] - The company focuses on merging advanced medical technology with finance and services to provide a full-process solution for ion therapy, including equipment layout, financial support, operation and maintenance, consulting services, personnel training, and big data services [1] Group 2: Product Development - The company has invested significantly in R&D for new products, recently developing the world's first light ion combined treatment device, which can provide proton and helium ion beams at 230 MeV/u for clinical treatment, as well as carbon ion beams for tumor treatment in specific body areas [1] - The new device occupies only 1500 m² and significantly reduces equipment and construction costs compared to traditional heavy ion therapy devices, addressing the high comprehensive investment issue associated with ion therapy [1] Group 3: Strategic Investment and Goals - The introduction of strategic investors will help Guoke Ion strengthen its core technological advantages, accelerate international market expansion, and stabilize its strategic planning while improving corporate governance [2] - The company plans to leverage its AI center to connect ion therapy devices nationwide, gather quality medical resources, and reconstruct the diagnosis and treatment process using intelligent technology to achieve strategic goals [2]